Every filing period on record, as reported. One column per filed period — a period with no column is a period with no filing, not a zero.
Basis · Amendments and terminations supersede the original report for the same registrant, client and period, so a revised quarter is counted once at its latest filed value. Registration-only filings carry no activity money and are excluded from these totals.
Who lobbies for them
Every outside firm that has filed on this client's behalf, by fees reported.
Issue areas declared on the filings, ranked by how many filings name each one.
Animals
ANI
80 filings
$44.2M on those filings
Budget/Appropriations
BUD
73 filings
$42.1M on those filings
Health Issues
HCR
Bills named in the filings
The 15 most-cited of 128 bill references, extracted from the activity descriptions.
H.R. 1458118th CongressAccess to Prescription Digital Therapeutics Act of 202312 filingsthrough 2024
S. 723118th CongressAccess to Prescription Digital Therapeutics Act of 202312 filingsthrough 2024
H.R. 1706111th CongressNamed in the filings; no matching bill record on file.
Who did the lobbying
Every lobbyist named on this client's filings.
Bill DavisBoehringer Ingelheim USA Corporation, Formerly Reported as Boehringer Ingelheim Pharmaceuticals, IncCovered position: Rep. Bob Gibbs - Legislative Aide37 filingsthrough 2026
Amy Chevalier EfantisBoehringer Ingelheim USA Corporation, Formerly Reported as Boehringer Ingelheim Pharmaceuticals, IncCovered position: LD, Rep. Artur Davis36 filingsthrough 2017
Mary Bridget WalshBoehringer Ingelheim USA Corporation, Formerly Reported as Boehringer Ingelheim Pharmaceuticals, IncCovered position: Sen. Bill Nelson - Legislative Assistant, Deputy Legislative Director; Sen. Jon Tester - Legislative Director, Deputy Chief of Staff and Acting Chief of Staff33 filingsthrough 2024
The filings
The 20 most recent of 119 filings. Every figure above is built from these records.
Period
Registrant
Type
Reported
Record
2nd Quarter (Apr 1 - June 30) 2026
Boehringer Ingelheim USA Corporation, Formerly Reported as Boehringer Ingelheim Pharmaceuticals, Inc
This record groups every filed spelling of the client's name into one entity, so "MERCK & CO., INC." and "MERCK & CO INC" read as the same company. The grouping is the client's normalized name — organizations that file under genuinely different names appear separately. Handle: boehringer-ingelheim-usa-corporation.
Reading this · LD-2 reports a hired firm's fee and a registrant's reported expenses on separate lines and never both on one filing, so the two lists above are different quantities and are ranked separately rather than against each other. Firm names link to their own record as the firms chapter lands.
65 filings
$50.6M on those filings
Medicare/Medicaid
MMM
64 filings
$46.9M on those filings
Agriculture
AGR
52 filings
$5.2M on those filings
Pharmacy
PHA
32 filings
$5.6M on those filings
Trade (domestic/foreign)
TRD
31 filings
$23.8M on those filings
Copyright/Patent/Trademark
CPT
30 filings
$22.4M on those filings
Consumer Issues/Safety/Products
CSP
21 filings
$12.8M on those filings
Defense
DEF
16 filings
$8.3M on those filings
Taxation/Internal Revenue Code
TAX
10 filings
$5.7M on those filings
Accounting
ACC
8 filings
$5.2M on those filings
Note · A filing names one to several issue areas and reports a single dollar figure for the period, so the same money appears beside every issue that filing declares. The dollar column is therefore spend on filings that named this issue — it is not a split of the total, and these figures sum above it. Filing counts do not double-count.
11 filings
through 2010
S. 469115th CongressAffordable and Safe Prescription Drug Importation Act10 filingsthrough 2018
S.Con.Res. 3115th CongressA concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.10 filingsthrough 2018
S. 5369111th CongressNamed in the filings; no matching bill record on file.9 filingsthrough 2010
H.R. 1492119th CongressTo amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.8 filingsthrough 2026
S. 832119th CongressEPIC Act of 20258 filingsthrough 2026
S. 2599117th CongressAgriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 20228 filingsthrough 2022
H.R. 3419118th CongressForeign Animal Disease Prevention, Surveillance, and Rapid Response Act of 20237 filingsthrough 2024
S. 1666118th CongressForeign Animal Disease Prevention, Surveillance, and Rapid Response Act of 20237 filingsthrough 2024
H.R. 19117th CongressLower Costs, More Cures Act of 20217 filingsthrough 2022
H.R. 3117th CongressElijah E. Cummings Lower Drug Costs Now Act7 filingsthrough 2022
H.R. 107116th CongressTo amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.7 filingsthrough 2020
How these are found · Bill references are extracted from the free-text activity description each filing writes, then matched to the Congress in session that filing year. A reference we can't match to a bill on file is still shown, unlinked — we cite what the filing said rather than guess at what it meant. Naming a bill is not a position on it: LD-2 records that a client lobbied on the bill, never which side.
Paul RomnessBoehringer Ingelheim USA Corporation, Formerly Reported as Boehringer Ingelheim Pharmaceuticals, IncCovered position: Amy Efantis, LD, Rep Artur Davis26 filingsthrough 2014
Thomas Allen HawksMonument AdvocacyCovered position: Minority Staff Director, Senate Committee on Agriculture, Nutrition, and Forestry; Chief of Staff, Legislative Director, Legislative Assistant, Deputy Legislative Director, Legislative Aide, U.S. Senator Thad Cochran (R-MS)23 filingsthrough 2026
Lilia Mcfarland HorderMonument AdvocacyCovered position: Acting Chief of Staff, Departmental Administration, USDA, Acting Chief of Staff, Office of the Deputy Secretary, USDA, Legislative Fellow (Detailed from USDA), Office of Senator Dianne Feinstein, Special Assistant23 filingsthrough 2026
Julian MalasiBoehringer Ingelheim USA Corporation, Formerly Reported as Boehringer Ingelheim Pharmaceuticals, Inc20 filingsthrough 2023
John WeberMonument AdvocacyCovered position: Legislative Director, Senior Policy Advisor, U.S. Rep. Dusty Johnson (R-SD); Legislative Assistant, Chairman Conaway, House Committee on Agriculture, Staff Assistant, U.S. Rep. Kristi Noem (R-SD), Intern, Senator John Thune (R-SD).18 filingsthrough 2026
Scott BennettBoehringer Ingelheim USA Corporation, Formerly Reported as Boehringer Ingelheim Pharmaceuticals, IncCovered position: Legislative Assistant, Congressman Bob Goodlatte (VA-06) August 2017 - April 2018 Legislative Director, Congressman Bob Goodlatte (VA-06) April 2018 - October 201816 filingsthrough 2025
Alanna Porter TemmeBoehringer Ingelheim USA Corporation, Formerly Reported as Boehringer Ingelheim Pharmaceuticals, Inc15 filingsthrough 2015
Candie PhippsBoehringer Ingelheim USA Corporation, Formerly Reported as Boehringer Ingelheim Pharmaceuticals, IncCovered position: Amy Efantis, LA, Rep Tom Barrett15 filingsthrough 2010
Michael TomberlinHance ScarboroughCovered position: Chief of Staff, Rep, Chip Cravaack, Chief of Staff, Rep. Louie Gohmert10 filingsthrough 2022
Leah D SvobodaBoehringer Ingelheim USA Corporation, Formerly Reported as Boehringer Ingelheim Pharmaceuticals, Inc9 filingsthrough 2019
Jonathan DorstBoehringer Ingelheim USA Corporation, Formerly Reported as Boehringer Ingelheim Pharmaceuticals, Inc9 filingsthrough 2017
John Kevin BrennanBluebird StrategiesCovered position: Chief of Staff, Rep. Rosa DeLauro (D-CT); Director, Rep. Sherrod Brown (D-OH); Legislative Assistant, Rep. Tom Foglietta (D-PA)5 filingsthrough 2024
Ryan DonnellyBoehringer Ingelheim USA Corporation, Formerly Reported as Boehringer Ingelheim Pharmaceuticals, Inc3 filingsthrough 2026
William DentBoehringer Ingelheim USA Corporation, Formerly Reported as Boehringer Ingelheim Pharmaceuticals, IncCovered position: Director, Federal Government Affairs. Sen. Marshall, Rep. John Joyce, Sen. Tillis, Rep. Buddy Carter2 filingsthrough 2026
Alexa FoxMonument AdvocacyCovered position: Intern, Staff Assistant, Legislative Correspondent and Legislative Aide, Legislative Assistant, Senior Legislative Assistant, Rep Jim Costa (D-CA).1 filingthrough 2026
Covered positions · 16 of 24 lobbyists named on these filings disclosed a prior government post. The text is reproduced exactly as filed.
